SPECIAL CONSIDERATIONS IN TREATING HYPERTENSION IN THE ELDERLYGAVRAS I; GAVRAS H.1980; GERIATRICS; ISSN 0016-867X; USA; DA. 1980; VOL. 35; NO 7; PP. 34-40; 4 P.; BIBL. 2 REF.Article

ANTIHYPERTENSIVE THERAPY WITH MK 421: ANGIOTENSIN II-RENIN RELATIONSHIPS TO EVALUATE EFFICACY OF CONVERTING ENZYME BLOCKADEBIOLLAZ J; BRUNNER HR; GAVRAS I et al.1982; JOURNAL OF CARDIOVASCULAR PHARMACOLOGY; ISSN 0160-2446; USA; DA. 1982; VOL. 4; NO 6; PP. 966-972; BIBL. 31 REF.Article

EFFECT OF PINDOLOL ON BLOOD PRESSURE, PLASMA RENIN ACTIVITY, AND CATECHOLAMINES IN HYPERTENSIVE PATIENTSGAVRAS I; GAVRAS H; TIFFT CP et al.1981; J. CLIN. PHARMACOL.; ISSN 0091-2700; USA; DA. 1981; VOL. 21; NO 2; PP. 79-83; BIBL. 16 REF.Article

EFFECT OF A NEW BETA-ADRENERGIC BLOCKER, L-BUNOLOL, ON BLOOD PRESSURE AND ON THE RENIN-ALDOSTERONE SYSTEM.GAVRAS H; GAVRAS I; BRUNNER HR et al.1977; J. CLIN. PHARMACOL.; U.S.A.; DA. 1977; VOL. 17; NO 5-6; PP. 350-357; BIBL. 1 P.Article

The antiarrhythmic potential of angiotensin II antagonism : Experience with losartanGAVRAS, I; GAVRAS, H.American journal of hypertension. 2000, Vol 13, Num 5, pp 512-517, issn 0895-7061, 1Article

THE ANTIHYPERTENSIVE ACTION OF METHYLDOPA IN RELATION TO ITS EFFECT ON THE RENIN-ALDOSTERONE SYSTEM.GAVRAS H; GAVRAS I; BRUNNER HR et al.1977; J. CLIN. PHARMACOL.; U.S.A.; DA. 1977; VOL. 17; NO 7; PP. 372-378; BIBL. 19 REF.Article

Bradykinin-mediated effects of ACE inhibitionGAVRAS, I.Kidney international. 1992, Vol 42, Num 4, pp 1020-1029, issn 0085-2538Conference Paper

Nifedipine in the treatment of essential hypertensionGAVRAS, I; GABRAS, H.Journal of clinical pharmacology. 1985, Vol 25, Num 6, pp 429-432, issn 0091-2700Article

IS ELEVATED PLASMA RENIN ACTIVITY OF PROGNOSTIC IMPORTANCE IN PROGRESSIVE SYSTEMIC SCLEROSIS.GAVRAS H; GAVRAS I; CANNON PJ et al.1977; ARCH. INTERN. MED.; U.S.A.; DA. 1977; VOL. 137; NO 11; PP. 1554-1558; BIBL. 18 REF.Article

Angiotensin inhibition and malignancies: a reviewROSENTHAL, T; GAVRAS, I.Journal of human hypertension. 2009, Vol 23, Num 10, pp 623-635, issn 0950-9240, 13 p.Article

The role of AII antagonists in hypertension : Focus on telmisartanGAVRAS, I; GAVRAS, H.Cardiovascular reviews & reports. 2000, Vol 21, Num 2, pp 76-80, issn 0197-3118Article

Angiotensin-converting enzyme inhibitors in hypertension and congestive heart failureGAVRAS, I; GAVRAS, H.Advances in internal medicine. 1990, Vol 35, pp 249-267, issn 0065-2822, 19 p.Article

ROLE OF VASOCONSTRICTOR SYSTEMS IN EXPERIMENTAL GLUCOCORTICOID-HYPERTENSION IN RATSWAEBER B; GAVRAS H; BRESNAHAN MR et al.1983; CLINICAL SCIENCE (1979); ISSN 0143-5221; GBR; DA. 1983; VOL. 65; NO 3; PP. 255-261; BIBL. 31 REF.Article

RECIPROCAL RELATION BETWEEN RENIN DEPENDENCY AND SODIUM DEPENDENCY IN ESSENTIAL HYPERTENSION.GAVRAS H; RIBEIRO AB; GAVRAS I et al.1976; NEW ENGL. J. MED.; U.S.A.; DA. 1976; VOL. 295; NO 23; PP. 1278-1283; BIBL. 26 REF.Article

ROLE OF VASOPRESSIN, CATECHOLAMINES, AND PLASMA VOLUME IN HYPERTONIC SALINE-INDUCED HYPERTENSIONHATZINIKOLAOU P; GAVRAS H; BRUNNER HR et al.1981; AM. J. PHYSIOL., HEART CIRC. PHYSIOL.; ISSN 0363-6135; USA; DA. 1981; VOL. 9; NO 6; PP. 827-831; BIBL. 12 REF.Article

BLOOD PRESSURE RESPONSE TO CENTRAL AND/OR PERIPHERAL INHIBITION OF PHENYLETHANOLAMINE N-METHYLTRANSFERASE IN NORMOTENSIVE AND HYPERTENSIVE RATSBLACK J; WAEBER B; BRESNAHAN MR et al.1981; CIRC. RES.; ISSN 0009-7330; USA; DA. 1981; VOL. 49; NO 2; PP. 518-524; BIBL. 34 REF.Article

PHYSIOLOGIC STUDIES WITH SARALASIN IN ANIMALSGAVRAS H; GAVRAS I; BRUNNER HR et al.1979; KIDNEY INTERNATION., SUPPL.; DEU; DA. 1979; NO 9; PP. 20-28; BIBL. 110 REF.Article

Contribution of bradykinin to maintenance of normal blood pressureGAVRAS, H; BENETOS, A; GAVRAS, I et al.Hypertension (Dallas, Tex. 1979). 1987, Vol 9, Num 6, pp 147-149, issn 0194-911X, 2Article

Stimulation of vasopressin by calcium microinjections in the area of the paraventricular nucleus of the hypothalamusBENETOS, A; GAVRAS, I; GAVRAS, H et al.Brain research. 1987, Vol 412, Num 1, pp 182-184, issn 0006-8993Article

SALT-INDUCED HYPERTENSION IN CHRONIC RENAL FAILURE: EVIDENCE FOR A NEUROGENIC MECHANISMDIPETTE D; WAEBER B; VOLICER L et al.1983; LIFE SCIENCES(1973); ISSN 0024-3205; GBR; DA. 1983; VOL. 32; NO 7; PP. 733-740; BIBL. 23 REF.Article

FATAL PANCYTOPENIA ASSOCIATED WITH THE USE OF CAPTOPRILGAVRAS I; GRAFF LG; ROSE BD et al.1981; ANN. INTERN. MED.; ISSN 0003-4819; USA; DA. 1981; VOL. 94; NO 1; PP. 58-59; BIBL. 8 REF.Article

ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421"GAVRAS H; WAEBER B; GAVRAS I et al.1981; LANCET (BR. ED.); ISSN 0140-6736; GBR; DA. 1981; NO 8246; PP. 543-546; BIBL. 26 REF.Article

Angiotensin II as a cardiovascular risk factorGAVRAS, I; GAVRAS, H.Journal of human hypertension. 2002, Vol 16, pp S2-S6, issn 0950-9240, SUP2Conference Paper

Effects of Eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters : Results from a 26-week, double-blind, multicentre studyGAVRAS, I; GAVRAS, H.Current medical research and opinion. 1999, Vol 15, Num 1, pp 15-24, issn 0300-7995Article

Cardioprotective potential of angiotensin-converting enzyme inhibitorsGAVRAS, I; GAVRAS, H.Clinical cardiology (Mahwah, NJ). 1991, Vol 14, Num 8, pp IV.68-IV.71, issn 0160-9289, SUP4Conference Paper